UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers
Go back to UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers| (NYSE: UCB) | Delayed: 34.63 +0.36 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.27 | 52 Week High | $ | |||
| Open | $34.50 | 52 Week Low | $ | |||
| Day High | $34.77 | P/E | N/A | |||
| Day Low | $34.47 | EPS | $ | |||
| Volume | 966,414 | |||||
